Bellevue: Truveta has announced a strategic collaboration with Pfizer to deliver new safety insights on a continuous basis, using verifiable real-world data at scale. Truveta will provide Pfizer with an unprecedented data platform for research. Pfizer will use de-identified data from Truveta to identify, monitor, and evaluate potential signals in near-real time, informing efforts to mitigate risks and enabling further research.
Truveta is the health system-led data platform with a vision of Saving Lives with Data. Truveta’s 20 health system members provide more than 16 percent of U.S. patient care from tens of thousands of clinical care sites across 42 states and provide ongoing governance to Truveta.
“Truveta’s dataset is one of the most timely and complete datasets available in the United States, allowing Pfizer to learn directly from de-identified patient data at an unprecedented pace and scale,” said Dr. Aida Habtezion, Chief Medical Officer, and Head of Worldwide Medical and Safety, Pfizer. “This enhances our best-in-class monitoring systems, through near real-time monitoring of safety signals in an expansive patient population. We hope to continue to find additional benefit from this growing data such as identifying and addressing health disparities.”
Read also: Pfizer, Moderna COVID vaccines get USFDA emergency use nod for kids as young as 6 months
“Truveta’s vision is Saving Lives with Data, and we are inspired to work with Pfizer to fight the devastating impacts of COVID-19 and other health conditions,” said Terry Myerson, CEO of Truveta. “We are excited to work closely with Pfizer as we build the largest and most complete data platform for U.S. health, readily accessible through a complete analytics solution. With Truveta, researchers can be empowered with real-time data to find cures, advance patient care, and transform healthcare in the U.S. The world needs answers to medical questions faster and together, we can help.”
Read also: Pfizer to acquire 8.1 percent stake in Valneva
Ruchika joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at [email protected] Contact no. 011-43720751
Editorial
Bronchial Asthma – Early Indicators for Diagnosis and Its Management in Indian Practice Settings
Role of metoprolol tartrate in management of acute myocardial infarction in the present era
Managing co-existing allergic rhinitis and asthma: Analyzing the role of Montelukast-levocetirizine…
Casirivimab/Imdevimab – An Indian Real World Experience : Review
Anti-diabetic drug and NASH: Current Options in 2022
Journal Club Today
E-cigarette use among adolescents may increase lifetime CVD risk
Health News Today
Health Bulletin 22/June/2022
